Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of non-hematologic characteristics and baseline chronic opioid dose
source: American journal of hematology
authors: Carroll CP, Cichowitz C, Yu T, Olagbaju YO, Nelson JA, Campbell T, Lanzkron Ssummary/abstract:
Despite its rarity in the United States, sickle cell disease accounts for a disproportionate amount of healthcare utilization and costs. The majority of this is due to acute care for painful crises. A small subpopulation of patients accounts for most these costs due to frequent visits to emergency departments and acute care facilities. Previous investigations have found that these high utilizing patients are distinguished by both a more severe disease course and certain non-hematologic characteristics, which may include higher socioeconomic status and some psychiatric and psychological characteristics. This prospective observational cohort study was undertaken to test the ability of these characteristics to prospectively predict acute pain care outcomes, including visit frequency, total opioid doses, and pain improvement at the Johns Hopkins Sickle Cell Infusion Center (SCIC).
Seventy-three participants were followed for 12 months and SCIC utilization and treatment outcomes were tabulated for 378 visits. Participants who visited the SCIC most frequently had markedly worse pain improvement despite higher within-visit opioid doses. Higher utilization was associated with indicators of greater illness severity, more aggressive treatment for sickle cell disease, higher baseline opioid doses, higher socioeconomic status, greater pain-related anxiety, and a history of psychiatric treatment. Overall, poor acute pain treatment response was associated with higher utilization and higher baseline opioid doses. The pattern of association between high utilization, poor acute care outcomes, and higher baseline opioid doses is discussed in terms of prior research and future directions.organization: The Johns Hopkins School of Medicine, USA; The Johns Hopkins School of Medicine and Bloomberg School of Public Health, USA; University of Maryland School of Medicine, USA; University of Colorado School of Medicine, USA; University of Rochester School of Medicine and Dentistry, USA
read more full text
A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)Limited evidence guides opioid dosing st...
Feasibility of an internet-enabled tablet-based guided imagery for stress and pain reduction intervention in adults ...Pain of sickle cell disease (SCD) has bo...
Sickle Cell Disease Coalition (SCDC)https://www.youtube.com/watch?v=oQP-Uq0B...
Sickle Cell Emergency Room Care: From Patients to Providershttps://www.youtube.com/watch?time_conti...
Living With Sickle Cell Disease: One Person’s Story of Pain and Prejudice and Their Hopes for a Stem Cell TherapyMy name is Marissa Cors, I have sickle c...
My medical school lesson was tinged with racism. Did that affect how I treated a sickle cell patient years later?The young woman was curled up in a ball....
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCDThe Green Park Collaborative (GPC) is wo...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.